Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2003 Jun;2(6):439-47.

The impact of drug-induced QT interval prolongation on drug discovery and development.

Author information

1
Pfizer Global Research and Development, Eastern Point Road MS 4083, Groton, Connecticut 06340, USA. bernard_fermini@groton.pfizer.com

Abstract

During the past decade, a number of non-cardiovascular drugs have had their label revised or have been withdrawn from the market because of unexpected post-marketing reports of sudden cardiac death associated with a prolongation of the QT interval, and an increased propensity to develop a ventricular tachyarrhythmia called Torsades de Pointes. Although a direct link between QT interval prolongation and arrhythmogenesis is still unclear, QT prolongation is now the subject of increased regulatory review and is considered a significant risk factor for predicting human safety of New Chemical Entities. Consequently, pharmaceutical companies are striving to improve the drug discovery and development process to identify, as early as possible, the risk of novel agents, or their metabolites, of causing QT interval prolongation and to make appropriate go/no-go decisions or modify their development programme accordingly.

PMID:
12776219
DOI:
10.1038/nrd1108
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center